BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shot up 13.9% during mid-day trading on Tuesday . The company traded as high as $3.10 and last traded at $2.86, with a volume of 3,156,108 shares traded. The stock had previously closed at $2.51.

A number of brokerages have recently issued reports on BDSI. Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Tuesday, July 5th. Cantor Fitzgerald reissued a “hold” rating on shares of BioDelivery Sciences International in a research report on Saturday. Laidlaw dropped their price target on BioDelivery Sciences International from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, March 14th. Roth Capital reissued a “buy” rating on shares of BioDelivery Sciences International in a research report on Monday, March 28th. Finally, FBR & Co reissued a “positive” rating and set a $12.00 price target on shares of BioDelivery Sciences International in a research report on Tuesday, March 29th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $8.38.

The firm has a 50-day moving average of $2.38 and a 200 day moving average of $3.23. The stock’s market cap is $150.60 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. During the same quarter in the prior year, the company earned ($0.16) EPS. The firm earned $3 million during the quarter, compared to analyst estimates of $2.96 million. The firm’s revenue was down 77.1% compared to the same quarter last year. On average, equities research analysts anticipate that BioDelivery Sciences International, Inc. will post ($1.19) earnings per share for the current year.

Other hedge funds and institutional investors recently bought and sold shares of the company. Bank of Montreal Can raised its position in BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock valued at $3,971,000 after buying an additional 28,838 shares in the last quarter. 1492 Capital Management LLC raised its position in BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock valued at $2,580,000 after buying an additional 41,069 shares in the last quarter. Royce & Associates LLC raised its position in BioDelivery Sciences International by 6.2% in the fourth quarter. Royce & Associates LLC now owns 1,487,800 shares of the specialty pharmaceutical company’s stock valued at $7,127,000 after buying an additional 87,200 shares in the last quarter. Sei Investments Co. raised its position in BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock valued at $1,584,000 after buying an additional 233,519 shares in the last quarter. Finally, Turner Investments L.P. raised its position in BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock valued at $4,315,000 after buying an additional 321,290 shares in the last quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.